FDA Grants Lantern Pharma Additional Orphan Drug Designation for Drug Candidate LP-184 in Glioblastoma Multiforme & Malignant Gliomas

Builds upon recent orphan drug designation (ODD) of LP-184 for the treatment of Pancreatic Cancer

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here